TAGUM DOCTORS COLLEGE INC.

Mahogany St., Rabe Subdivision Tagum City

Bachelor of Science in Nursing

DRUG STUDY

Lapidez, Alma V. 521

Name of Patient : Room/Bed No. : Rating:
Age : 49 yrs. old Physician: Dr. Renegado
Gender : Female Admitting Diagnosis: AGE with mild dehydration r/o UTI
Chief Complaints : Abdominal pain Student’s Name and Group: Sian, Liza P. – BSN2, Group 2

Date Name of Drug Classification Dosage/ Mechanism of Indication Contraindications Adverse Nursing
Time/Route Action Reaction Responsibilities
Mar. Brand name: Antacids, Via IVTT: Description:  Symptomatic  Clostridium CNS:  Assess other
18, Antireflux 40 mg Omeprazole is a gastroesopga difficile infection headache, medications patient
2018 Agents & OD substituted eal reflux  Inadequate dizziness, may be taking for
Generic Antiulcerants benzimidazole disease Vitamin B12 asthenia effectiveness and
name: gastric (GERD)  low amount of GI: interactions
antisecretory agent without magnesium in diarrhea, (especially those
Omeprazole and is also known esophageal the blood abdominal dependent on
as PPI. It blocks lesions  Liver Problems pain, cytochrome P450
the final step in  Erosive  Interstitial nausea, metabolism or those
Drug Image: gastric acid esophagitis Nephritis vomiting, dependent on acid
secretion by and  subacute constipatio environment for
specific inhibition of accompanying cutaneous n, absorption).
H+/K+ ATPase symptoms lupus flatulence  Monitor therapeutic
enzyme system caused by erythematosus Musculosk effectiveness and
present on the GERD  Systemic Lupus eletal: adverse reactions at
secretory surface  Maintenance Erythematosus back pain beginning of therapy
of the gastric of healing Respirator
 Osteoporosis and periodically
parietal cell. Both erosive y: cough,
 Broken Bone throughout therapy.
basal and esophagitis upper
 CYP2C19 Poor respiratory  Assess GI system:
stimulated acid are  Pathologic Metabolizer
inhibited. tract bowel sounds every
hypersecretor  Hypersensitivity
Onset: Approx 1 infection 8hours, abdomen for
y conditions to drug or its
hr. Skin: rash pain and swelling,
eg Zollinger- components
Duration: Up to 72 appetite loss.
Ellison
 hr. syndrome  Monitor hepatic
Pharmacokinetics  Duodenal enzymes: AST, ALT,
: ulcer (short increased alkaline
Absorption: Rapid term phosphatase during
but variably treatment) treatment.
absorbed (oral).  Helocobacter  Assess
Bioavailability: pylori ibfection knowledge/teach
Oral: Approx 30- and duodenal appropriate use of this
40%. Time to peak ulcer disease, medication,
plasma to eradicate interventions to
concentration: H.pylori with reduce side effects,
Approx 1-2 hr. clarithromycin and adverse
Distribution: Plas (dual therapy) symptoms to report.
ma protein binding:  H.pylori
Approx 95%.  Caution patient to
infection and
Metabolism: Hepa avoid alcohol,
duodenal
tic metabolism via salicylates, ibuprofen:
ulcer disease,
CYP2C19 may cause GI
to eradicate
isoenzyme to form irritation
H.pylori with
hydroxyl- clarithromycin  Patient may
omeprazole and and experience anorexia;
CYP3A4 to form amoxicillin small frequent meals
omeprazole (triple therapy) may help to maintain
adequate nutrition
sulfone.  Short-term
Excretion: Mainly treatment of  Report severe
via urine (approx active benign headache, unresolved
77%), the ulcer severe diarrhea, or
remainder in changes in respiratory
faeces (via the status. Inform
bile). Elimination physician if patient is
half-life: 0.5-3 hr. or intends to become
pregnant. Breast-
feeding is not
recommended.

Reference: www.mims.com/philippines/drug/info/